

WHY LIVMARLI?

600+ PATIENTS WITH ALAGILLE SYNDROME

HAVE USED LIVMARLI TO HELP
TREAT CHOLESTATIC PRURITUS^{1-3*}



Backed by
**>5 years of
safety data**^{1,2†}



Prescribed by
>120 health care providers
in the United States³



Exceptional
**access and
patient support**

LIVMARLI is an FDA-approved treatment for cholestatic pruritus
in patients with Alagille syndrome who are ≥ 3 months of age.¹

*Number includes all patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI in clinical studies, as well as those treated in the United States commercially and through the expanded access program.

†The majority of exposure occurred without a placebo control in open-label extensions.

Please see full Important Safety Information at LIVMARLIhcp.com
and full Prescribing Information for LIVMARLI.



**INDICATED FOR
ADULTS, TOO!**

 **Livmarli**[®]
(maralixibat) oral solution

**TO FIND OUT WHY
ANY LEVEL OF CHOLESTATIC PRURITUS
DESERVES TO BE TREATED,
PLEASE CONTACT YOUR REGIONAL ACCOUNT MANAGER**



To learn more, visit LIVMARLIhcp.com

References: 1. LIVMARLI® (maralixibat) oral solution. Prescribing Information. Mirum Pharmaceuticals, Inc. 2. Raman RK, Garner W, Vig P, Tucker E. An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome. Poster presented at: European Association for the Study of the Liver (EASL): International Liver Congress; June 23-26, 2021. 3. Data on file. REF-00349. Mirum Pharmaceuticals, Inc.

Please see full Important Safety Information at LIVMARLIhcp.com and full Prescribing Information for LIVMARLI.

INDICATION

LIVMARLI is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older.

SELECTED IMPORTANT SAFETY INFORMATION

Warnings: Liver Test Abnormalities, Gastrointestinal Symptoms (diarrhea, abdominal pain, vomiting) and Fat-Soluble Vitamin Deficiency may occur; consider dose reduction or treatment interruption as needed.



© 2023 – Mirum Pharmaceuticals, Inc.
All rights reserved. US-LIV-2300308v2 12/2023

